Actively Recruiting
Safety and Immune Response Study of V132 Vaccine Compared to Pneumococcal Vaccines in Healthy Adults Aged 50 to 75
Led by Merck Sharp & Dohme LLC · Updated on 2026-10-20
280
Participants Needed
10
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the safety and immune response of the V132 vaccine in healthy older adults aged 50 to 75 years. This Phase 1, randomized, double-blind, comparator-controlled trial aims to evaluate different dose levels of V132 vaccine formulations compared to existing pneumococcal vaccines. The study focuses on understanding how well V132 is tolerated and how it stimulates the immune system in this healthy adult population. Participants will receive single intramuscular doses of one of three V132 vaccine formulations or one of two active comparator vaccines, PREVNAR 20 or CAPVAXIVE, at varying dose levels. The doses for part 2 of the study will be chosen based on safety and immune response data from part 1 and will not exceed the highest dose tested initially. The study includes two parts a dose escalation phase and a dose expansion phase. During the study, participants will be monitored closely for immediate reactions within 30 minutes of vaccination, injection-site and systemic side effects up to 7 days after vaccination, and other adverse events for up to 12 months. Immune response will be measured by specific antibody activity before and 28 days after vaccination. The total study duration extends up to 12 months to ensure comprehensive safety and immunogenicity assessment in healthy older adults.
CONDITIONS
Brief Title
A Study of V132 in Healthy Older Participants (V132-001)
Research Team
T
Toll Free Number
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here